What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate
Public Health · 2024-06 · 231 · 148-153
DOI: 10.1016/j.puhe.2024.03.018 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Public Health, 2024-06. Verfasst von A Roediger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of International Health, Care and Public Health Research Institute - CAPHRI, Faculty of Health, Medicine and Life Sciences, Maastricht Uni…. Hauptthemen laut MEDLINE: Drug Costs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: Unfair medicines prices have been discussed widely as an obstacle for patient access. This article aims to structure the discussion about fair pricing of medicines, analyses the elements for a fair price, and assesses its practical implications. METHODS: A systematic literature research has been undertaken and complemented by gray literature. Definitions and elements of a fair price have been extracted from the sample, categorized via a thematic and a quantitative analysis, and mirrored against the traditional framework of 'iustum pretium' (fair price). RESULTS: The most often attributes of a fair price mentioned were affordability (n = 30), followed by value and research and development (R&D) investment (n = 20). Other frequently mentioned attributes are profitability (n = 19), transparency of R&D costs (n = 18), cost-effectiveness (n = 17), and manufacturing (n = 14). Nearly all definitions present fair price as a balance between different objectives. CONCLUSIONS: Most publications stipulate that medicines are a common good and should be affordable. At the same time, most publications also propose a pricing approach based on covering costs for R&D and/or on value. Consequently, most of the attempts to clarify fair price result in a value-affordability dilemma, which does not necessarily warrant patient access. Many social health systems implement pricing regardless of the debate. This systematic review offers a set of attributes for fair price and helps refining the existing pricing and reimbursement regulations. Once complemented by empirical datapoints, it provides the basis for developing a framework for fair pricing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of International Health, Care and Public Health Research Institute - CAPHRI, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. Electronic address: alexander.ro…
- Faculty of Arts and Social Sciences, University of Zurich, Switzerland.
- Department of International Health, Care and Public Health Research Institute - CAPHRI, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Zitieren
APA
Roediger, A., Schönbächler, G., & Brand, H. (2024). What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate. Public Health, 231, 148-153. https://doi.org/10.1016/j.puhe.2024.03.018
Vancouver
Roediger A, Schönbächler G, Brand H. What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate. Public Health. 2024;231:148-153. doi:10.1016/j.puhe.2024.03.018
BibTeX
@article{Roediger2024,
author = {Roediger, A and Schönbächler, G and Brand, H},
title = {What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate},
journal = {Public Health},
year = {2024},
volume = {231},
pages = {148--153},
doi = {10.1016/j.puhe.2024.03.018}
}
EUVIMED